Jürgen Erbe

Schultze & Braun: Dr. Jürgen Erbe secures future of Heidelberg clinic proaesthetic

View on LinkedIn – see current LinkedIn likes

Insolvency administrator Dr. Jürgen Erbe of Schultze & Braun has secured the future of the Heidelberg clinic for plastic and cosmetic surgery proaesthetic GmbH, the firm announced on 12 October 2026. Central Aesthetics took over the business operations as of 1 October 2026; the contracts have been signed.

Jürgen Erbe
Jürgen Erbe

According to the firm, almost all of the clinic’s more than 30 employees were taken over, and the business will remain at its known address in Heidelberg. Patient care was ensured throughout the process, as the transfer was carried out during ongoing clinic operations.

Improving law firms’ results in
Chambers and Co. since 2004.
200+ law firms advised worldwide.
Customers include Eversheds, Freshfields, Taylor Wessing and others.
Learn more

Law Business

Dr. Jürgen Erbe said he was very pleased to have found in Central Aesthetics a buyer from the industry that brings the necessary know-how and fits the range of services and strategic orientation of proaesthetic. Sandro Stroh, managing director of Central Aesthetics, said proaesthetic fits optimally into its portfolio.

Proaesthetic has been providing medical services in plastic, aesthetic and cosmetic surgery as well as minimally invasive aesthetic medicine since 1993.

For detailed information, as well as the picture copyright, please see the law firm’s original article here: https://www.schultze-braun.de/news/aus-proaesthetic-wird-central-aesthetics-dr-juergen-erbe-sichert-zukunft-von-heidelberger-schoenheitsklinik

More news

Trending news

FSM Rechtsanwälte has advised IFP Immobilien Freizeit Parken-Wiener Neustadt GmbH on the sale of a property portfolio comprising 35 properties
JDP Drapała Chomiuk & Partners has again been ranked in the IFLR1000 2026 in two categories, M&A and Project Development,
Elvinger Hoss Prussen has advised PSG Equity on the set-up and final close of PSG Europe III, a growth equity